{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:29:07Z","timestamp":1760549347146},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2013,2,20]],"date-time":"2013-02-20T00:00:00Z","timestamp":1361318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s12325-013-0012-9","type":"journal-article","created":{"date-parts":[[2013,2,28]],"date-time":"2013-02-28T18:55:02Z","timestamp":1362077702000},"page":"203-211","source":"Crossref","is-referenced-by-count":10,"title":["Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome"],"prefix":"10.1007","volume":"30","author":[{"given":"Maria I.","family":"Vazquez-Roque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernest P.","family":"Bouras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,2,20]]},"reference":[{"key":"12_CR1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1572-0241.2004.04114.x","volume":"99","author":"PD Higgins","year":"2004","unstructured":"Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol. 2004;99:750\u2013759.","journal-title":"Am J Gastroenterol"},{"key":"12_CR2","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1111\/j.1365-2036.2007.03540.x","volume":"26","author":"RS Choung","year":"2007","unstructured":"Choung RS, Locke GR, 3rd, Schleck CD, et al. Cumulative incidence of chronic constipation: a population-based study 1988\u20132003. Aliment Pharmacol Ther. 2007;26:1521\u20131528.","journal-title":"Aliment Pharmacol Ther"},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1586\/egh.11.30","volume":"5","author":"M Vazquez Roque","year":"2011","unstructured":"Vazquez Roque M, Camilleri M. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation. Expert Rev Gastroenterol Hepatol. 2011;5:301\u2013310.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/BF01537261","volume":"34","author":"JE Everhart","year":"1989","unstructured":"Everhart JE, Go VL, Johannes RS, et al. A longitudinal survey of self-reported bowel habits in the United States. Dig Dis Sci. 1989;34:1153\u20131162.","journal-title":"Dig Dis Sci"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/BF01536339","volume":"34","author":"A Sonnenberg","year":"1989","unstructured":"Sonnenberg A, Koch TR. Physician visits in the United States for constipation: 1958 to 1986. Dig Dis Sci. 1989;34:606\u2013611.","journal-title":"Dig Dis Sci"},{"key":"12_CR6","first-page":"43","volume":"19","author":"BC Martin","year":"2006","unstructured":"Martin BC, Barghout V, Cerulli A. Direct medical costs of constipation in the United States. Manag Care Interface. 2006;19:43\u201349.","journal-title":"Manag Care Interface"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1477-7525-7-20","volume":"7","author":"ME Bongers","year":"2009","unstructured":"Bongers ME, Benninga MA, Maurice-Stam H, et al. Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood. Health Qual Life Outcomes 2009;7:20.","journal-title":"Health Qual Life Outcomes"},{"key":"12_CR8","first-page":"460","volume":"47","author":"JP Wang","year":"2008","unstructured":"Wang JP, Duan LP, Ye HJ, et al. [Assessment of psychological status and quality of life in patients with functional constipation]. Zhonghua Nei Ke Za Zhi. 2008;47:460\u2013463. In Chinese.","journal-title":"Zhonghua Nei Ke Za Zhi."},{"key":"12_CR9","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1007\/s10620-011-1639-5","volume":"56","author":"SX Sun","year":"2011","unstructured":"Sun SX, Dibonaventura M, Purayidathil FW, et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56:2688\u20132695.","journal-title":"Dig Dis Sci"},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1053\/gast.2002.37095","volume":"123","author":"DA Drossman","year":"2002","unstructured":"Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123:2108\u20132131.","journal-title":"Gastroenterology"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11894-009-0039-x","volume":"11","author":"BM Spiegel","year":"2009","unstructured":"Spiegel BM. The burden of IBS: looking at metrics. Curr Gastroenterol Rep. 2009;11:265\u2013269.","journal-title":"Curr Gastroenterol Rep"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1358\/dof.2011.036.06.1594078","volume":"36","author":"M Vazquez Roque","year":"2011","unstructured":"Vazquez Roque M, Camilleri M. Velusetrag. Drugs Future. 2011;36:447\u2013454.","journal-title":"Drugs Future"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1056\/NEJMoa0800670","volume":"358","author":"M Camilleri","year":"2008","unstructured":"Camilleri M, Kerstens R, Rykx A, et al. A placebocontrolled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344\u20132354.","journal-title":"N Engl J Med"},{"key":"12_CR14","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1038\/ajg.2011.285","volume":"106","author":"BS Wong","year":"2011","unstructured":"Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol. 2011;106:2154\u20132164.","journal-title":"Am J Gastroenterol"},{"key":"12_CR15","first-page":"375","volume":"52","author":"KA Lucas","year":"2000","unstructured":"Lucas KA, Pitari GM, Kazerounian S, et al. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev. 2000;52:375\u2013414.","journal-title":"Pharmacol Rev"},{"key":"12_CR16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.lfs.2010.03.015","volume":"86","author":"AP Bryant","year":"2010","unstructured":"Bryant AP, Busby RW, Bartolini WP, et al. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract. Life Sci. 2010;86:760\u2013765.","journal-title":"Life Sci"},{"key":"12_CR17","first-page":"403","volume":"9","author":"LA Harris","year":"2007","unstructured":"Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther. 2007;9:403\u2013410.","journal-title":"Curr Opin Mol Ther"},{"key":"12_CR18","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1172\/JCI119683","volume":"100","author":"S Schulz","year":"1997","unstructured":"Schulz S, Lopez MJ, Kuhn M, et al. Disruption of the guanylyl cyclase-C gene leads to a paradoxical phenotype of viable but heat-stable enterotoxin-resistant mice. J Clin Invest. 1997;100:1590\u20131595.","journal-title":"J Clin Invest"},{"key":"12_CR19","first-page":"A464","volume":"128","author":"RW Busby","year":"2005","unstructured":"Busby RW, Bryant AP, Cordero EA, et al. The molecular target of MD-1100 is guanylate cyclase-C (GC-C), an apical receptor on intestinal epithelial cell. Gastroenterology. 2005;128:A464.","journal-title":"Gastroenterology"},{"key":"12_CR20","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ejphar.2010.09.019","volume":"649","author":"RW Busby","year":"2010","unstructured":"Busby RW, Bryant AP, Bartolini WP, et al. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit. Eur J Pharmacol. 2010;649:328\u2013335.","journal-title":"Eur J Pharmacol"},{"key":"12_CR21","first-page":"A464","volume":"128","author":"AP Bryant","year":"2005","unstructured":"Bryant AP, Busby RW, Cordero EA, et al. MD-1100, a therapeutic agent in development for the treatment of IBS-C, enhances intestinal secretion and transit, decreases visceral pain and is minimally absorbed in rats. Gastroenterology. 2005;128:A464.","journal-title":"Gastroenterology"},{"key":"12_CR22","first-page":"T2034","volume":"130","author":"AP Bryant","year":"2006","unstructured":"Bryant AP, Busby RW, Cordero EA, et al. The characterization of an active metabolite of MD-1100, a therapeutic agent in development for the treatment of IBS-C and chronic constipation. Gastroenterology. 2006;130:T2034.","journal-title":"Gastroenterology"},{"key":"12_CR23","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1365-2982.2009.01385.x","volume":"22","author":"H Eutamene","year":"2010","unstructured":"Eutamene H, Bradesi S, Larauche M, et al. Guanylate cyclase C-mediated antinociceptive effects of linaclotide in rodent models of visceral pain. Neurogastroenterol Motil. 2010;22:312\u2013e384.","journal-title":"Neurogastroenterol Motil"},{"key":"12_CR24","doi-asserted-by":"crossref","first-page":"S699","DOI":"10.1016\/S0016-5085(12)62701-2","volume":"142","author":"JHA Castro","year":"2012","unstructured":"Castro JHA, Hughes PA, Martin C, et al. Mechanism of action for linaclotide induced abdominal pain relief. Gastroenterology. 2012;142:S699.","journal-title":"Gastroenterology"},{"key":"12_CR25","volume-title":"Microbia succesfully completes phase IA trial of MD-1100 for IBS-C and other GI disorders","author":"S Brady","year":"2005","unstructured":"Brady S. Microbia succesfully completes phase IA trial of MD-1100 for IBS-C and other GI disorders. 2005. Available at: http:\/\/www.ironwoodpharma.com\/newsPDF\/2005_05.17.Microbia.IBS.IA.pdf . Accessed Sep 1 2012."},{"key":"12_CR26","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.14309\/00000434-200509001-00894","volume":"100","author":"MG Currie","year":"2005","unstructured":"Currie MG, Kurtz CB, Mahajan-Miklos S, et al. Effects of single dose administration of MD-1100 on safety, tolerability, exposure, and stool consistency in healthy subjects. Am J Gastroenterol. 2005;100:S328.","journal-title":"Am J Gastroenterol"},{"key":"12_CR27","first-page":"A","volume":"130","author":"CB Kurtz","year":"2006","unstructured":"Kurtz CB, Fitch DA, Busby RW, et al. Effects of multidose administration of MD-1100 on safety, tolerability, exposure, and pharmacodynamics in healthy subjects. Gastroenterology. 2006;130:A\u201326. Abstract 132.","journal-title":"Gastroenterology"},{"key":"12_CR28","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1053\/j.gastro.2007.06.067","volume":"133","author":"V Andresen","year":"2007","unstructured":"Andresen V, Camilleri M, Busciglio IA, et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology. 2007;133:761\u2013768.","journal-title":"Gastroenterology"},{"key":"12_CR29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/ajg.2008.59","volume":"104","author":"JM Johnston","year":"2009","unstructured":"Johnston JM, Kurtz CB, Drossman DA, et al. Pilot study on the effect of linaclotide in patients with chronic constipation. Am J Gastroenterol. 2009;104:125\u2013132.","journal-title":"Am J Gastroenterol"},{"key":"12_CR30","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1053\/j.gastro.2009.12.050","volume":"138","author":"AJ Lembo","year":"2010","unstructured":"Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886\u2013895.e1.","journal-title":"Gastroenterology"},{"key":"12_CR31","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1053\/j.gastro.2010.08.041","volume":"139","author":"JM Johnston","year":"2010","unstructured":"Johnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010;139:1877\u20131886.e2.","journal-title":"Gastroenterology"},{"key":"12_CR32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1056\/NEJMoa1010863","volume":"365","author":"AJ Lembo","year":"2011","unstructured":"Lembo AJ, Schneier HA, Shiff SJ, et al. Two randomized trials of linaclotide for chronic constipation. N Engl J Med. 2011;365:527\u2013536.","journal-title":"N Engl J Med"},{"key":"12_CR33","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1038\/ajg.2012.255","volume":"107","author":"S Rao","year":"2012","unstructured":"Rao S, Lembo AJ, Shiff SJ, et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am J Gastroenterol. 2012;107:1714\u20131724.","journal-title":"Am J Gastroenterol"},{"key":"12_CR34","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/ajg.2012.254","volume":"107","author":"WD Chey","year":"2012","unstructured":"Chey WD, Lembo AJ, Lavins BJ, et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebocontrolled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012;107:1702\u20131712.","journal-title":"Am J Gastroenterol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0012-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-013-0012-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0012-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T00:10:33Z","timestamp":1595463033000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0012-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,20]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0012-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,20]]}}}